Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Other Non-Current Assets (2016 - 2026)

Corcept Therapeutics (CORT) has disclosed Other Non-Current Assets for 15 consecutive years, with $5.2 million as the latest value for Q1 2026.

  • For Q1 2026, Other Non-Current Assets fell 22.04% year-over-year to $5.2 million; the TTM value through Mar 2026 reached $5.2 million, down 22.04%, while the annual FY2025 figure was $5.2 million, 22.04% down from the prior year.
  • Other Non-Current Assets hit $5.2 million in Q1 2026 for Corcept Therapeutics, roughly flat from $5.2 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $8.3 million in Q2 2025 and bottomed at $1.8 million in Q2 2022.
  • Average Other Non-Current Assets over 5 years is $5.7 million, with a median of $6.4 million recorded in 2024.
  • Year-over-year, Other Non-Current Assets crashed 55.7% in 2022 and then soared 140.62% in 2023.
  • Corcept Therapeutics' Other Non-Current Assets stood at $5.1 million in 2022, then rose by 29.32% to $6.5 million in 2023, then grew by 1.05% to $6.6 million in 2024, then fell by 22.04% to $5.2 million in 2025, then changed by 0.0% to $5.2 million in 2026.
  • According to Business Quant data, Other Non-Current Assets over the past three periods came in at $5.2 million, $5.2 million, and $8.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.